Poulikos Poulikakos: The evolving landscape of CDK4/6 targeting therapies
Poulikos Poulikakos, Professor at Icahn School of Medicine at Mount Sinai, shared his recent article on LinkedIn:
“Our review article, “Resistance Mechanisms and Therapeutic Strategies for CDK4/6 Kinase Targeting in Cancer,” is out today in Nature Cancer!
Check it out.
The review discusses the evolving landscape of CDK4/6 targeting therapies. We outline mechanisms of tumor resistance to CDK4/6 inhibitors and highlight novel pharmacologic strategies, including selective degradation and improved targeting of CDK4/6 and CDK2, as well as CDK paralog selective inhibitors and degraders.
Emerging roles of CDK4/6 inhibitors in cancer immunotherapy are also discussed, paving the way for new directions in treatment design.
Together these recent advances in understanding mechanisms and drug discovery efforts enable the design of more effective CDK-targeting strategies for cancer therapy.”
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.
Authors: James J. Asciolla, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023